We believe that drug development is both science and a fine art. Our approach to multi-disciplinary integration delivers results faster to achieve the outcomes you deserve. DDC aims the pharmaceutical development of Dihydroorotate Dehydrogenase inhibitors and has the goal of bringing its best molecule, DDC#1, to the clinical stage within 1 or 2 years. DDC#1 is a potential new drug for the treatment of Acute Myeloid Leukemia (AML) and COVID-19 that could significantly improve patient’s survival rate.
Our multidisciplinary Team, led by professionals with a long track record in Drug Development and Clinic, relies on highly skilled personnel with unique competence in developing integrated solutions.